image
Healthcare - Biotechnology - NASDAQ - US
$ 0.6156
-2.15 %
$ 4.44 M
Market Cap
-0.54
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SILO stock under the worst case scenario is HIDDEN Compared to the current market price of 0.616 USD, Silo Pharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SILO stock under the base case scenario is HIDDEN Compared to the current market price of 0.616 USD, Silo Pharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SILO stock under the best case scenario is HIDDEN Compared to the current market price of 0.616 USD, Silo Pharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SILO

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6$0.4$0.415 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
72.1 K REVENUE
0.00%
-4.71 M OPERATING INCOME
-22.05%
-4.39 M NET INCOME
-18.70%
-3.83 M OPERATING CASH FLOW
-18.90%
974 K INVESTING CASH FLOW
123.48%
3.24 M FINANCING CASH FLOW
788.07%
18 K REVENUE
0.00%
-1.09 M OPERATING INCOME
39.66%
-1.03 M NET INCOME
40.40%
-1.64 M OPERATING CASH FLOW
-78.79%
871 K INVESTING CASH FLOW
2413.87%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Silo Pharma, Inc.
image
Current Assets 7.11 M
Cash & Short-Term Investments 7.08 M
Receivables 0
Other Current Assets 31 K
Non-Current Assets 300 K
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 300 K
95.53 %4.05 %Total Assets$7.4m
Current Liabilities 1.66 M
Accounts Payable 0
Short-Term Debt 0
Other Current Liabilities 1.66 M
Non-Current Liabilities 722 K
Long-Term Debt 0
Other Non-Current Liabilities 722 K
69.65 %30.35 %Total Liabilities$2.4m
EFFICIENCY
Earnings Waterfall Silo Pharma, Inc.
image
Revenue 72.1 K
Cost Of Revenue 5.84 K
Gross Profit 66.3 K
Operating Expenses 4.77 M
Operating Income -4.71 M
Other Expenses -313 K
Net Income -4.39 M
500k500k00(500k)(500k)(1m)(1m)(1m)(1m)(2m)(2m)(2m)(2m)(3m)(3m)(3m)(3m)(4m)(4m)(4m)(4m)(5m)(5m)72k(6k)66k(5m)(5m)313k(4m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
91.90% GROSS MARGIN
91.90%
-6526.44% OPERATING MARGIN
-6526.44%
-6092.59% NET MARGIN
-6092.59%
-87.26% ROE
-87.26%
-59.27% ROA
-59.27%
-81.76% ROIC
-81.76%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Silo Pharma, Inc.
image
500k500k00(500k)(500k)(1m)(1m)(1m)(1m)(2m)(2m)(2m)(2m)(3m)(3m)(3m)(3m)(4m)(4m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -4.39 M
Depreciation & Amortization 6.18 K
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital 552 K
Others 553 K
Free Cash Flow -3.83 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Silo Pharma, Inc.
image
SILO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Silo Pharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
4.33 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
6.72 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The novel therapeutic platform centers on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. globenewswire.com - 3 weeks ago
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. *Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK , June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA). The novel therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. prnewswire.com - 3 weeks ago
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders”) that Silo licenses from Columbia University. globenewswire.com - 1 month ago
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset Strategic decision positions Company to diversify treasury holdings with a long-term digital store of value Strategic decision positions Company to diversify treasury holdings with a long-term digital store of value globenewswire.com - 1 month ago
Silo Wellness to Relist as Born Defense, a National Security Investment Issuer Focused on Ending Forever Wars and Upholding the Just War Doctrine Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo," or the "Company") is pleased to announce a proposed name change to "Born Defense" and a change of business to become an investment issuer focused on the defense and national security space guided by the Just War Doctrine1 and committed to ending so-called "forever wars"2 ("Proposed Transaction"). The Company will now focus on building a business aligned with peace through strength and responsible national self-defense. newsfilecorp.com - 1 month ago
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 Study is expected to deliver final device data and documentation needed for planned FDA IND submission Study is expected to deliver final device data and documentation needed for planned FDA IND submission globenewswire.com - 1 month ago
Silo Pharma Announces Closing of $2 Million Public Offering SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant. The Series A-1 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire five years thereafter. The Series A-2 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire eighteen months thereafter. globenewswire.com - 2 months ago
Silo Pharma Announces Pricing of $2 Million Public Offering SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant. The Series A-1 Warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire five years thereafter. The Series A-2 Warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire eighteen months thereafter. The closing of the offering is expected to occur on or about May 16, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com - 2 months ago
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). “We look forward to working with Veloxity Labs for GLP sample analysis in our current safety study of SPC-15,” said Eric Weisblum, CEO of Silo. globenewswire.com - 2 months ago
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market globenewswire.com - 2 months ago
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study — Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26's potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia. All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation. globenewswire.com - 2 months ago
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer's disease (AD) exclusively licensed to Silo Pharma from Columbia University. globenewswire.com - 2 months ago
8. Profile Summary

Silo Pharma, Inc. SILO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 4.44 M
Dividend Yield 0.00%
Description Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Contact 677 N. Washington Boulevard, Sarasota, FL, 34236 https://silopharma.com
IPO Date Jan. 8, 2021
Employees 3
Officers Mr. Eric Weisblum Chairman, President & Chief Executive Officer Mr. Daniel E. Ryweck Chief Financial Officer